Terazol Cream

Quick links

Choose a section

Quick links to important sections

Advertisements

Terazol Cream

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Terazol Cream

What is Terazol Cream? (Terconazole Vaginal)

Property Description
Active ingredient Terconazole
Form Vaginal Cream
Pharmacological class Azole Antifungal Drug
Route of administration Topical/Vaginal
Origin Synthetic

What Type of Medicine is Terazol Cream?

Terazol Cream is a pharmaceutical preparation classified as an antifungal drug, specifically belonging to the azole class of antimycotic agents, and is available exclusively by prescription. The drug entity is defined by its single active component, Terconazole, which is a synthetic triazole derivative engineered to fight infections caused by susceptible fungi. This placement within the triazole subclass relates to its utility in addressing local fungal overgrowth.

Terconazole: Composition and General Purpose

The composition centers on the Terconazole molecule, which is formulated within an emulsion cream base. This finished product, known as a Vaginal Cream, is a specific dosage form designed to facilitate topical delivery through vaginal administration. This form is specifically intended for adult women who require local treatment. The active ingredient is used in local therapy to address certain fungal organisms, establishing it as a primary therapeutic option for this category of infection. The general purpose is to provide local treatment by acting as an effective antimycotic agent against fungal infection.

Differentiation and Mechanism Summary

Terconazole is distinguished within the azole class by its specific triazole structure, which is designed to disrupt the growth of fungal pathogens. Unlike some older antifungals, this agent is packaged as a cream specifically for local administration, which minimizes systemic exposure and concentrates the therapeutic effect where needed. These agents function by preventing the fungus from building its protective cell membrane, which halts its ability to grow and spread. This mechanism is key to ensuring the drug achieves its goal of neutralizing the fungal organism at the local treatment site.

Advertisements

What side effects are possible with Terazol Cream?

Possible side effects and safety information

The official safety profile for Terazol Cream (Terconazole Vaginal Cream) documents a range of adverse reactions, which are classified by regulatory agencies based on clinical trial incidence and post-marketing reports. The most frequently documented reactions from clinical trials include headache, dysmenorrhea (painful menstruation), genital burning and itching, and abdominal pain, all classified as common (incidence ge 2%). Systemic symptoms such as fever and chills were reported in less than 2% of patients.


Safety Classifications and Organ Systems

Adverse effects are categorized into several System-Organ Classes (SOCs), including Reproductive System Disorders, Nervous System Disorders, and General Disorders and Administration Site Conditions. The product is strictly contraindicated in patients with a known hypersensitivity to terconazole or any other component of the cream.


Serious Adverse Reactions and Special Populations

Rare but serious adverse reactions reported during post-marketing surveillance include Anaphylaxis and Toxic Epidermal Necrolysis (TEN). Furthermore, the label advises specific safety considerations for certain patient groups. Terconazole is classified as Pregnancy Category C; therefore, its use is generally not recommended during the first trimester unless the potential benefit outweighs the fetal risk. Safety and effectiveness have not been established in females under 18 years old. Regulatory documents also specify that the medication should be discontinued if systemic symptoms, such as fever, chills, or flu-like illness, or if severe irritation or sensitization develops.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Profile

The official regulatory documentation for Terazol Cream establishes that overdosage in humans has not been formally reported to date, which informs the entire official overdose profile. Consequently, no specific, formally documented clinical manifestations, signs, or symptom clusters of overdose are listed in the prescribing information. Furthermore, no specific severe or life-threatening outcomes resulting from human overdosage are detailed in these regulatory sources.

The primary factor requiring immediate attention is exposure outside of the intended route. The product is explicitly labeled for vaginal use only and is not for oral or ophthalmic administration. Therefore, immediate medical attention is required for any known or suspected overdose, most notably following the accidental oral ingestion of the cream.

Mandated Treatment and Monitoring

  • No specific antidote is known for the active ingredient, Terconazole.
  • Management of a suspected overdose is limited to symptomatic and supportive treatment, which is the regulator-defined procedural intervention when specific reversal agents are unavailable.
  • Clinical monitoring in a healthcare setting is generally indicated following significant accidental exposure to manage any potential systemic effects.
  • No population-specific considerations (e.g., for pediatric, elderly, or impaired patients) are formally documented in the official overdose sections of the labeling.
Advertisements

Therapeutic Uses of Terazol Cream

What Terazol Cream Treats: Main Uses and Benefits

Terazol Cream is a therapy generally used for the local management of conditions characterized by acute or disruptive episodes, specifically Vulvovaginal Candidiasis (VVC), often referred to as a vaginal yeast infection. The medication is applied across therapeutic domains where additional symptomatic support is needed to address symptoms linked to the fungal cause.


This antifungal intervention is commonly used across conditions presenting with recurrent or episodic manifestations. The primary therapeutic purpose of Terazol Cream is supporting the management of conditions linked to the Candida fungal organism, thereby contributing to eased discomfort. It is relevant for managing symptom clusters that may become intense or disruptive, such as pruritus (itching), burning, soreness, and abnormal discharge.

It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Acute Symptoms
Supports the patient in managing inflammatory discomfort and assists with functional stability when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Terazol Cream — Official Regulatory Information


Eligibility Scope

Classification Population or Condition
Allowed Adult women diagnosed with vulvovaginal candidiasis.
Contraindicated Patients with known hypersensitivity to terconazole or any component of the cream.
Not Recommended Female pediatric patients (safety/effectiveness not established).
Restricted Use First trimester of pregnancy (use only if deemed essential).

Official Eligibility Statements

  • The medicine is contraindicated in patients with a known allergy to the drug or its components.
  • Safety and effectiveness have not been established in female pediatric patients.
  • Use is not recommended in the first trimester of pregnancy; however, it may be used in the second and third trimesters if the potential benefit outweighs the possible risks.
  • A decision must be made to discontinue nursing or discontinue the drug when used by nursing mothers.
  • Concurrent use with rubber or latex products (e.g., condoms, diaphragms) is not recommended.
  • Use must be discontinued upon the occurrence of systemic symptoms such as fever or chills.

Connection to the Overall Eligibility Profile

Official regulatory documents define the eligible user base for Terazol Cream primarily as adult women who do not possess a documented hypersensitivity to the formulation. Eligibility is strictly constrained across developmental states, prohibiting established use in children and restricting use during the first trimester of pregnancy. Furthermore, a specific caution is documented concerning concurrent use with common latex or rubber contraceptive barriers.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile for Terazol Cream is established based on its low systemic absorption following localized administration. The official documentation of potential interactions addresses both systemic effects and local physical constraints, adhering strictly to official label text.


Pharmacological Interaction Profile

Official regulatory labeling documents that the therapeutic outcome of this medicine is not affected by oral contraceptive usage. This statement confirms the absence of a known clinically significant exposure-altering interaction between the topical antifungal and systemic hormonal contraceptives. Furthermore, no known interactions are formally documented between the product and food or drinks. The official regulatory status regarding the effect of consuming alcohol while using this medicine is noted as unknown.

Physical Compatibility Restrictions

The most specific restriction detailed in the official prescribing information relates to a physical incompatibility with certain types of barrier contraceptives. The base material contained in the related suppository formulation may interact with and potentially cause damage to rubber or latex products, specifically those used for vaginal contraceptive diaphragms or latex condoms. Due to the risk of compromising the integrity of these physical barriers, official guidance states that concurrent use is not recommended. This constraint is tied to the physical properties of the medicine’s base material.

Advertisements

Mechanism of Action

Targeted Inhibition of the Fungal Cell Factory

Terconazole acts as a highly selective inhibitor of the fungal enzyme 14 alpha-lanosterol demethylase ( CYP51). This enzyme is crucial for the fungus to synthesize ergosterol, the key component maintaining the integrity of its cell membrane, similar to cholesterol in human cells.


Dual Action Leading to Structural Failure

The blockage of the CYP51 enzyme initiates a cascade: it simultaneously depletes the fungal cell of essential ergosterol while causing the toxic buildup of intermediary sterols . This dual assault causes the fungal cell membrane to lose its structural stability and become leaky. This loss of cellular integrity is the core physiological effect, contributing to the inhibition of growth and cell death of the fungal organism.


Mechanistic Selectivity and Constraints

The drug exhibits selective toxicity due to its significantly greater affinity for the fungal CYP51 enzyme than for analogous human enzymes; this difference concentrates the mechanism's action on the pathogen. However, the mechanism can be physiologically constrained if the fungal organism develops genetic mutations or increases the activity of efflux pumps, which may result in a reduction of the drug's effective concentration at its molecular target.

Advertisements

Dosage and Administration Information

How Terazol Cream is Used: Administration Guidelines

This section outlines the standardized usage protocol for terconazole cream and suppositories. This information is based on standardized prescribing parameters.


Administration Scope and Dosage

Feature Guideline
Route of Administration Strictly intravaginal (topical use only). The product is not approved for oral or ophthalmic use.
Standard Dosing One full applicator (5 grams) of either the 0.4% or 0.8% cream concentration.
Frequency and Timing Applied once daily (QD), typically administered at bedtime to ensure optimal retention of the medication at the treatment site.

Course Duration and Use Conditions

The duration of the course is defined by the formulation strength:

Formulation Required Duration
0.4% Vaginal Cream 7 consecutive days
0.8% Vaginal Cream 3 consecutive days
80 mg Vaginal Suppository 3 consecutive days

Special Procedural Conditions:

  • Menstruation: The treatment course is designed to continue uninterrupted through the menstrual cycle.
  • Pediatric Use: The safety and effectiveness of this medicine have not been established in patients younger than 18 years of age.
  • Retreatment: Before initiating a subsequent course of therapy, the diagnosis must be reconfirmed by laboratory methods to ensure the appropriate pathogen is still present.

Protocol Summary

The protocol involves the use of a measured dose applicator for the prescribed cream concentration, applied once daily at the designated time of bedtime for a short, fixed duration of three or seven days. This structural approach defines the standardized administration of terconazole for local therapy.

Advertisements

Recent Clinical Evidence

Terazol Cream: Recent Clinical Evidence


Evidence for Use in Vulvovaginal Candidiasis (VVC)

Terazol Cream was studied for Vulvovaginal Candidiasis (VVC), a condition characterized by fluctuating or episodic manifestations. The primary evidence comes from Randomized Controlled Trials (RCTs). In these studies, researchers monitored several measures, including outcomes related to physical discomfort and laboratory confirmation of fungal presence. The main measurement used was Therapeutic Cure, defined as the concurrent measurement of symptom resolution and a negative culture for Candida species. Findings describe patterns observed in these studies compared to those receiving other active treatments or a placebo, contributing to the understanding of symptom changes.


Studies on Pathogen Type and Severity

Research also explored studies conducted in patients with Severe VVC where symptoms were more intense or disruptive. The majority of the available evidence is related to VVC caused by the strain, Candida albicans. However, research exploring outcomes against infections caused by other, less common Candida species is limited. The evidence base for these specific situations remains limited; most studies explored outcomes related to the strain, C. albicans.


️ Durability of Response and Long-Term Follow-up

The clinical research focuses on measuring outcomes describing episodic or acute changes. Follow-up visits were typically observed in studies examining the frequency of mycological eradication and potential symptom relapse around Day 21 to Day 35 post-treatment. Research contributes to the broader evidence landscape regarding these short-term changes. However, there is limited information for long-term outcomes that look far beyond this four-to-five-week period.


Research in Special Populations

The research that examined Terazol Cream focused primarily on adult women, and the results apply only to the populations studied. Data for certain groups remain insufficient. Specifically, the large-scale clinical trials did not include enough subjects aged 65 and over to fully explore potential differences in observed patterns. Furthermore, the medicine was not evaluated in pre-menarchal females (children), and thus, no evidence exists for this group.


What Remains Uncertain About the Research Base

The clinical research still has specific gaps. Data for certain groups remain insufficient, especially for women aged 65 and older. Additionally, follow-up durations were primarily focused on the short-to-intermediate term. Finally, findings were mixed when looking at infections caused by specific, less common strains of Candida. Research highlights what is known—and what is still uncertain—emphasizing that findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Study Details | Safety and Equivalence of a Terconazole Vaginal Suppository... in the Treatment of Vulvovaginal Candidiasis (NCT00803738)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Terazol Cream (FAQ)

Q: Can men use Terazol Cream for a fungal infection?

A: Terazol Cream is officially approved only for treating vulvovaginal candidiasis, which affects adult women. The official product documentation does not include information or approval for the use of this medicine in men for fungal infections or any other condition.


Q: What should I do if I accidentally swallow a small amount of Terazol Cream?

A: Terazol Cream is designed strictly for topical vaginal use and should not be swallowed. If the cream is accidentally ingested or gets into the eyes or mouth, contacting a healthcare professional or poison control is generally recommended.


Q: Is it okay to have sex while I am using Terazol Cream?

A: Patient instructions for Terconazole often recommend refraining from sexual intercourse during the full course of treatment. Additionally, official regulatory documents caution that the cream and its related products may damage latex barrier contraceptives, which is another reason why concurrent use is not recommended. Specific guidance on this matter should be discussed with a healthcare provider.


Q: Is there a generic version of Terazol Cream available?

A: Yes, according to official drug status information, a generic version containing the active ingredient, terconazole vaginal cream, is available. The generic version is chemically the same as the brand-name product.


Q: Does Terazol Cream treat any infections other than yeast infections?

A: The official documentation indicates that Terazol Cream is specifically indicated for the treatment of vulvovaginal candidiasis, which is a yeast infection. This medicine is an antifungal agent and is not approved for the treatment of bacterial infections or other causes of vaginal itching.


Q: Can Terazol Cream be used by women who have diabetes?

A: Official labeling does not list diabetes as a contraindication for the use of Terazol Cream. However, clinical studies sometimes note that effectiveness may require careful management if the patient has underlying health conditions. It is important that any such conditions be discussed with a healthcare professional before beginning treatment.


Q: Do I need to refrigerate or store Terazol Cream in a special way?

A: According to regulatory storage requirements, Terazol Cream must be stored at controlled room temperature, which is generally between 20^circ–25^circC (68^circ–77^circF). It is important to protect the cream from freezing and excess heat to maintain its effectiveness.


Q: Can Terazol Cream cause headaches or body aches?

A: Yes, official safety information indicates that headaches are a very commonly reported side effect in clinical trials. Less frequently, systemic symptoms such as body aches, fever, or chills (flu-like illness) have also been reported.


Q: How long does the drug (terconazole) stay in the system after stopping the cream?

A: Official pharmacokinetic studies, which track how the body processes the drug, show that terconazole has a half-life in the bloodstream of approximately 6.9 hours following vaginal use. The half-life refers to the time it takes for half of the drug to be eliminated from the body.


Q: Does Terazol Cream stain clothing or sheets?

A: Patient information commonly advises that the cream may leak out of the vagina after application, which could potentially stain clothing or bed sheets. For this reason, wearing a sanitary napkin or panty liner while undergoing treatment is often suggested.


Q: Do you wash off Terazol Cream after a certain amount of time?

A: No, the cream is not meant to be washed out after application. It is typically applied once daily at bedtime to ensure the medication stays at the treatment site for the longest possible duration to achieve optimal effectiveness.


Q: Is it normal to see some discharge after applying Terazol Cream?

A: As a vaginal cream, the product is expected to leak out of the vagina. Patients are generally advised that they may need to wear a sanitary pad to manage this discharge, although the product label does not specifically describe the appearance or consistency of the post-application discharge.


Q: What research has been done on the safety of Terazol Cream for long-term use?

A: Official clinical research focuses on the short, fixed treatment periods of 3 or 7 days, with follow-up typically extending only a few weeks post-treatment. Consequently, there is limited information available from regulatory studies regarding the safety of Terazol Cream for use beyond this short-term scope.


Q: Does Terazol Cream have any effect on bacterial infections?

A: Terazol Cream is classified as an azole antifungal agent. Official clinical guidance confirms it is not intended for the treatment of bacterial infections, such as bacterial vaginosis, and patients with non-fungal infections are typically excluded from clinical trials.


Q: What are the main risks associated with using Terazol Cream?

A: The main risks documented in official warnings include the potential for hypersensitivity or allergic reactions, which may require immediate discontinuation. Additionally, the product is specifically cautioned against concurrent use with latex contraceptives due to the risk of physical damage to the barrier.


Q: Can I use Terazol Cream while breastfeeding?

A: Official labeling advises caution regarding use while breastfeeding. Since there are no data available on whether the drug is present in human milk, a decision must be made by a healthcare professional to either discontinue nursing or discontinue the drug, based on the benefit to the mother.


Q: How does the concentration of the medication in Terazol Cream compare to the suppositories?

A: Terazol Cream is available in two concentrations, 0.4% and 0.8%. The related suppository formulation contains a single strength of 80 mg. Both are designed to provide effective local treatment.


Q: What if I accidentally miss a dose of Terazol Cream?

A: Official patient instructions typically provide guidance for missed doses, often advising to apply it as soon as remembered unless it is nearly time for the next scheduled application. Specific instructions regarding missed doses should be confirmed with the prescribing information or a pharmacist.


Q: Are there any known interactions between Terazol Cream and herbal supplements?

A: The official product documentation confirms the absence of known interactions with common items like oral contraceptives, food, and drinks. However, the regulatory label does not specifically address or list potential interactions with herbal supplements or vitamins.


Q: What should I do if my symptoms get worse after starting Terazol Cream?

A: If your symptoms do not improve after a few days of treatment or if they become worse, prompt consultation with a healthcare professional is generally advised. The medication must also be discontinued if you experience severe irritation, sensitization, or systemic symptoms like fever or chills.


Q: Is it possible to be resistant to Terazol Cream?

A: Official warnings acknowledge the possibility of reduced effectiveness due to drug resistance. This is why official guidelines require the diagnosis to be reconfirmed by a lab test to ensure the appropriate pathogen is still present before initiating a subsequent course of therapy.


Q: Are there dietary changes that help Terazol Cream work better?

A: No known interactions between Terazol Cream and food or drinks are documented in official regulatory labeling. Consequently, there are no specific dietary changes officially recommended to enhance the drug's effectiveness.


Q: What is the potential for Terazol Cream to interact with over-the-counter pain relievers?

A: Regulatory documents do not detail any known pharmacological interactions between Terazol Cream and systemic medications, including common over-the-counter pain relievers. This is attributed to the drug’s low systemic absorption when applied vaginally.


Q: Is Terazol Cream the same as other yeast infection creams like Monistat?

A: Terazol Cream belongs to the azole class of antifungal drugs, with the active ingredient terconazole. While it shares the same purpose as other yeast infection treatments, they may contain different active ingredients, such as miconazole or clotrimazole, which belong to the same class.


Q: What are the most common side effects people experience with Terazol Cream?

A: According to clinical trials, the most commonly reported adverse events are headaches, painful menstruation (dysmenorrhea), and local symptoms like genital burning and itching. Other systemic symptoms, such as abdominal pain, have also been reported commonly.


Q: Can Terazol Cream cause a burning sensation when first applied?

A: Yes, genital burning and itching are listed in the official safety profile as common side effects associated with the use of Terazol Cream. This local irritation may be noticeable when the cream is first applied.


Q: Is it normal to have some itching after the first few applications of Terazol Cream?

A: Itching in the genital area is documented as a common side effect of Terazol Cream treatment. However, if local irritation, such as itching, becomes severe or worsens over time, official regulatory documents state that discontinuation of the drug and consulting a healthcare professional is necessary.


Q: Does Terazol Cream interact with birth control pills?

A: Official regulatory labeling explicitly states that the effectiveness of oral contraceptive usage is not affected by Terazol Cream. The local application of the medicine results in minimal systemic absorption, making a significant drug interaction with hormonal birth control unlikely.


Q: Does Terazol Cream affect condoms or diaphragms?

A: Official guidance warns that the base material in the cream and related suppositories may physically interact with and damage products made of rubber or latex, such as condoms and diaphragms. Because this could compromise the barrier's integrity, concurrent use is not recommended.


Q: Is it safe to use Terazol Cream during pregnancy?

A: Terazol Cream is generally not recommended during the first trimester of pregnancy due to its classification as Pregnancy Category C. However, it may be used in the second and third trimesters only if a healthcare provider determines that the potential benefit outweighs any potential risk to the fetus.


Q: Can Terazol Cream be used for recurring yeast infections?

A: The medicine is approved for treating acute vulvovaginal candidiasis. Official guidance states that if a patient requires retreatment, the diagnosis must be reconfirmed by a lab test to ensure the appropriate pathogen is still present before initiating a subsequent course of therapy.


Q: Can I apply Terazol Cream at any time of day?

A: Official administration guidelines recommend applying the cream once daily at bedtime. This timing is suggested to ensure the medication remains at the treatment site for the longest possible duration to achieve optimal effectiveness.

Advertisements

How should Terazol Cream be stored and disposed of?

How to Store and Dispose of Terazol Cream

Terazol Cream (Terconazole) must be stored according to regulatory labeling to maintain its stability and effectiveness.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20°–25°C or 68°–77°F).
Environment Protect from excess heat, moisture, and direct light.
Protection Do not freeze. Keep the cream in the original, tightly closed container.
Safety Keep the medicine out of the reach and sight of children.

Disposal Instructions

To dispose of unused or expired Terazol Cream, utilize a medication take-back program if one is available. If no take-back program exists, the medication must be mixed with an unappealing substance (such as dirt or cat litter) and sealed in a container before being placed in the trash. Do not flush this medication down a toilet or pour it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Terazol Cream found in:

A-Z Index: